10x Genomics (NASDAQ:TXG – Get Free Report) and Health Catalyst (NASDAQ:HCAT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Profitability
This table compares 10x Genomics and Health Catalyst’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 10x Genomics | -13.13% | -12.88% | -10.03% |
| Health Catalyst | -31.67% | -7.21% | -3.28% |
Valuation and Earnings
This table compares 10x Genomics and Health Catalyst”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 10x Genomics | $610.78 million | 2.39 | -$182.63 million | ($0.70) | -16.74 |
| Health Catalyst | $306.58 million | 0.64 | -$69.50 million | ($1.51) | -1.85 |
Health Catalyst has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 2.6% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for 10x Genomics and Health Catalyst, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 10x Genomics | 1 | 8 | 6 | 0 | 2.33 |
| Health Catalyst | 0 | 8 | 3 | 0 | 2.27 |
10x Genomics currently has a consensus target price of $13.65, suggesting a potential upside of 16.50%. Health Catalyst has a consensus target price of $4.73, suggesting a potential upside of 68.83%. Given Health Catalyst’s higher possible upside, analysts plainly believe Health Catalyst is more favorable than 10x Genomics.
Risk & Volatility
10x Genomics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
Summary
10x Genomics beats Health Catalyst on 8 of the 14 factors compared between the two stocks.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
